Every state, kept current
The Rates plan
$29/mo7-day free trialThis page shows one representative rate per state for Q2053. Full schedules include every locality, modifier, and age-band variant.
- Every code on all 51 published schedules
- Full-schedule CSV export and state network lists
- Email alerts when a state changes its rates
$29/mo after the trial. Cancel anytime.
Publishing states
17
Median % of Medicare
--
Rate range
$5,101.04 - $528,759.00
Q2053 rates in every publishing state
| State | Medicaid rate | % of Medicare | Prior auth | Vintage |
|---|---|---|---|---|
| Arkansas | $454,860.00 | -- | -- | 2026 |
| Arizona | $510,103.92 | -- | -- | 2026 |
| California | $97,858.12 | -- | -- | 2026 |
| Connecticut | $489,450.20 | -- | -- | 2026 |
| District of Columbia | $489,450.20 | -- | Required | 2026 |
| Idaho | $422,884.97 | -- | Required | 2026 |
| Indiana | $528,759.00 | -- | Required | 2026 |
| Kansas | $510,103.92 | -- | -- | 2026 |
| Michigan | $510,103.92 | -- | -- | 2026 |
| Mississippi | $489,450.20 | -- | -- | 2026 |
| Montana | $489,450.20 | -- | -- | 2026 |
| New Hampshire | $503,580.00 | -- | Required | 2026 |
| New Mexico | $488,038.00 | -- | -- | 2025 |
| Rhode Island | $505,880.76 | -- | -- | 2026 |
| South Carolina | $5,101.04 | -- | -- | 2026 |
| Texas | $489,720.00* | -- | -- | 2026 |
| Virginia | $489,290.60* | -- | -- | 2026 |
Published Medicaid fee-for-service schedule amounts, not a coverage or eligibility guarantee. Managed-care plan rates can differ. Where no prior-authorization flag is shown, the state does not publish one. Rows marked * are representative published variants or methodology-derived rates. "--" in the prior-auth column means the state publishes no PA flag.
Related state-specific services codes
- C1716 - Brachytherapy source, non-stranded, gold-198, per source
- C1717 - Brachytherapy source, non-stranded, high dose rate iridium-192, per source
- C1719 - Brachytherapy source, non-stranded, non-high dose rate iridium-192, per source
- C2616 - Brachytherapy source, non-stranded, yttrium-90, per source
- C2634 - Brachytherapy source, non-stranded, high activity, iodine-125, greater than 1.01 mci (nist), per source
- C2635 - Brachytherapy source, non-stranded, high activity, palladium-103, greater than 2.2 mci (nist), per source
- C2636 - Brachytherapy linear source, non-stranded, palladium-103, per 1 mm
- C2638 - Brachytherapy source, stranded, iodine-125, per source
All 12 codes from Q2009 to Q2058 or every state-specific services code by number.
Frequently asked questions
How much does Medicaid pay for Q2053?
17 state Medicaid programs publish a fee-for-service rate for Q2053 (brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose), ranging from $5,101.04 in South Carolina to $528,759.00 in Indiana. The full table on this page lists every publishing state's current rate.
Which state pays the most for Q2053?
Indiana publishes the highest Medicaid rate for Q2053 at $528,759.00. South Carolina publishes the lowest at $5,101.04.
Does Q2053 require prior authorization under Medicaid?
4 of the 17 publishing states flag Q2053 as requiring prior authorization (always or conditionally) on their fee schedules. States without a flag publish no PA indicator for this code - that means "not published", not "no PA required".